RCUS - Arcus Biosciences, Inc.
| Previous Close | 8.53 |
| Open | 8.49 |
| Bid | 8.18 x 800 |
| Ask | 8.24 x 900 |
| Day's Range | 8.13 - 8.57 |
| 52 Week Range | 7.15 - 16.06 |
| Volume | 63,581 |
| Avg. Volume | 171,741 |
| Market Cap | 363.851M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.20 |
- Simply Wall St.•8 days ago
If You Had Bought Arcus Biosciences (NYSE:RCUS) Stock A Year Ago, You'd Be Sitting On A 30% Loss, Today
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
- Benzinga•23 days ago
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...
- Business Wire•26 days ago
Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Eric Hoefer has joined the Company as Chief Commercial Officer. Mr. Hoefer will oversee all aspects of the Company’s global commercial strategy and operations as the Company works to ensure that it most efficiently leverages the clinical and market development opportunities for its therapeutic candidates.
- Business Wire•last month
Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that the Company will host a conference call and live webcast on Tuesday, June 25, 2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on its clinical and preclinical programs. Following the live webcast, a replay will be available on the Company’s website for approximately 30 days. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has several programs targeting important oncology/immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.
- GuruFocus.com•last month
Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $172,382 of Shares
CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 21,738 shares of RCUS on 06/06/2019 at an average price of $7.93 a share.
- Business Wire•2 months ago
Arcus Biosciences to Present Preliminary Data from the Ongoing Phase 1 Dose-Escalation Trials of AB928 in Combination with Chemotherapy or AB122 at the 2019 ASCO Annual Meeting
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the Company will be presenting preliminary data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual A2a/A2b receptor antagonist, in a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31-June 4, 2019. The activation of these receptors by adenosine interferes with the activity of key populations of immune cells and inhibits an optimal anti-tumor immune response.
- Business Wire•2 months ago
Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 4 pm ET at the Grand Hyatt, in New York, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.
- Insider Monkey•2 months ago
Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy?
Is Arcus Biosciences, Inc. (NYSE:RCUS) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
- Zacks•2 months ago
Infinity (INFI) Earnings and Sales Miss Estimates in Q1
Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.
- Business Wire•3 months ago
Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates
- Selected 150 mg for the dose expansion trial for AB928, the Company’s dual A2a/A2b receptor antagonist, in combination with AB122, the Company’s anti-PD-1 antibody
- Business Wire•3 months ago
Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that William Grossman, M.D., Ph.D. has joined the Company as Chief Medical Officer. Dr. Grossman will oversee all aspects of the Company’s global clinical development strategy and operations. “We are pleased to have Dr. Grossman join Arcus during this seminal period in the advancement and expansion of our clinical development programs,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.
- Business Wire•3 months ago
Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, today announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus’s clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy. As part of this partnership, Arcus will gain access to Strata’s drug development platform, featuring leading capabilities to design and conduct transformative precision therapy studies.
- Zacks•3 months ago
Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results
- Zacks•3 months ago
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
- Simply Wall St.•3 months ago
What Kind Of Shareholders Own Arcus Biosciences, Inc. (NYSE:RCUS)?
If you want to know who really controls Arcus Biosciences, Inc. (NYSE:RCUS), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to...
- Zacks•3 months ago
Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Arcus Biosciences, Inc. (RCUS).
- Business Wire•4 months ago
Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Rekha Hemrajani as Chief Operating and Financial Officer. Ms. Hemrajani will be responsible for several key areas, including finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources. “We are thrilled to welcome Rekha as a key member of our senior leadership team, as we enter an exciting period in Arcus’s development with multiple Phase 1 readouts for AB928, our dual A2a/A2b receptor antagonist, AB154, our anti-TIGIT antibody, and AB680, our small-molecule CD73 inhibitor,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.
- Zacks•4 months ago
Infinity Inks Deal With Roche for Phase II Study of IPI-549
Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.
- Business Wire•5 months ago
Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates
- Ended 2018 with four molecules in clinical development, including AB928, the Company’s dual A2aR/A2bR receptor antagonist, which is being evaluated in several dose-escalation tri
- Business Wire•5 months ago
Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced seven presentations at the 2019 American Association for Cancer Research Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia.
- Business Wire•5 months ago
Arcus Biosciences Announces Participation at Upcoming Investor Conference
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 am ET at the Lotte New York Palace, in New York, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.
- Motley Fool•6 months ago
Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today
Even in a surging market, these stocks fell. Find out why.
- Business Wire•6 months ago
Arcus Biosciences Announces Transition of Chief Financial and Operating Officer
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Jennifer Jarrett will step down as the Company’s Chief Financial and Operating Officer, effective January 11, 2019, to pursue an opportunity at a privately-held transportation and technology company. Ms. Jarrett will remain actively engaged with the Company and has been appointed to Arcus’s Board of Directors commencing January 12, 2019. Ms. Jarrett and the Company have also entered into a consulting agreement that will ensure a seamless transition.
- American City Business Journals•7 months ago
Here are the winners and losers from Bay Area's IPO class of 2018
Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.
